Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

Chemotherapy for breast cancer may be more effective during specific stages of the menstrual cycle, according to data from ...

2. Ovarian Cancer: Research indicates that a woman's chance of developing ovarian cancer may be influenced by hormonal ...

Jan. 22, 2025 — Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone ...